Heger Sabine, Kuester Rolf M, Volk Ruth, Stephani Ulrich, Sippell Wolfgang G
Division of Paediatric Endocrinology, Department of Paediatrics, Christian-Albrechts-University, University Hospital Schleswig-Holstein, Campus Kiel, Schwanenweg 20, D-24105 Kiel, Germany.
Brain Dev. 2006 Jun;28(5):300-4. doi: 10.1016/j.braindev.2005.10.006. Epub 2006 Feb 14.
Satoyoshi syndrome is a rare multisystemic disorder with assumed autoimmune pathogenesis. Typical clinical features are progressive painful muscle spasms, alopecia, diarrhoea, and skeletal and endocrine abnormalities often resulting in early invalidism and death. Patients have been treated with immunoglobulins and glucocorticoids with varying outcome. We report on a 19-year-old German adolescent who has been successfully treated with a new combination of carbamazepine to reduce the severity and frequency of painful nocturnal muscle spasms, prednisolone, methotrexate and sex-steroids. Prednisolone treatment alone was not successful. After introduction of low-dose of methotrexate to the therapy the patient recovered from muscle spasms, alopecia and diarrhoea. Initiation of sex-steroid treatment resulted in pubertal development, regular menstrual cycles and improved quality of life.
痛性痉挛综合征是一种罕见的多系统疾病,推测其发病机制为自身免疫性。典型的临床特征为进行性疼痛性肌肉痉挛、脱发、腹泻以及骨骼和内分泌异常,常导致过早残疾和死亡。患者曾接受免疫球蛋白和糖皮质激素治疗,疗效各异。我们报告了一名19岁的德国青少年患者,其采用卡马西平、泼尼松龙、甲氨蝶呤和性激素的新组合进行治疗,成功减轻了夜间疼痛性肌肉痉挛的严重程度和发作频率。单独使用泼尼松龙治疗未获成功。在治疗中引入小剂量甲氨蝶呤后,患者的肌肉痉挛、脱发和腹泻症状有所缓解。开始使用性激素治疗后,患者出现青春期发育、月经周期规律,生活质量得到改善。